文献速递肝病消化道肿瘤与早癌

口服抗病毒治疗启动时HBeAg状态对慢性乙型肝炎患者肝癌风险的影响

Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-09-06

本研究在韩国慢性乙型肝炎队列中评估启动恩替卡韦或替诺福韦时HBeAg状态与肝细胞癌(HCC)风险的关系,并在高加索PAGE-B队列中验证。韩国队列共9143例,中位随访5.1年,916例(10.0%)发生HCC;HBeAg阳性在非肝硬化亚组中与较低HCC风险独立相关,在肝硬化亚组无此关联。

要点

  • 非肝硬化慢性乙肝患者启动抗病毒治疗时HBeAg阳性与较低HCC风险独立相关。
  • 肝硬化亚组中HBeAg状态与HCC风险无显著关联。
  • 高加索验证队列非肝硬化亚组HBeAg阳性者无HCC发生,但差异未达统计学显著。

核心结论

  • 在无肝硬化的慢性乙型肝炎患者中,启动口服抗病毒治疗时HBeAg阳性似乎是HCC风险较低的独立因素,但在肝硬化患者中无此关联。

研究设计与样本

  • 多国队列研究,韩国队列纳入9143例启动恩替卡韦或替诺福韦的慢性乙型肝炎患者(平均年龄49.2岁),并在高加索PAGE-B队列(n=719)中验证。

主要发现

  • 韩国队列中位随访5.1年,916例(10.0%)发生HCC;整个队列及肝硬化亚组中基线HBeAg阳性与HCC风险无关。
  • 韩国非肝硬化亚组中,HBeAg阳性在多变量分析(aHR 0.41,95%CI 0.26-0.66)、倾向评分匹配(aHR 0.46,95%CI 0.28-0.76)和逆概率加权分析(aHR 0.44,95%CI 0.28-0.70)中均与较低HCC风险独立相关。
  • 高加索队列(平均年龄51.8岁,HBeAg阳性20.3%,肝硬化34.8%)中,整个队列及肝硬化亚组HBeAg阳性与HCC风险无关;非肝硬化亚组HBeAg阳性组无HCC发生,但差异未达统计学显著(aHR 0.21,95%CI 0.00-1.67)。

临床怎么用

  • 对于无肝硬化的慢性乙型肝炎患者,启动抗病毒治疗时HBeAg阳性可提示HCC风险相对较低,但仍需按指南进行HCC监测。
  • 肝硬化患者无论HBeAg状态如何,均应视为HCC高风险人群并坚持监测。

局限性

  • 高加索验证队列非肝硬化亚组中HBeAg阳性者无HCC发生,但差异未达统计学显著,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Antiviral treatment from hepatitis B envelope antigen (HBeAg)-positive status may attenuate the integration of hepatitis B virus DNA into the host genome causing hepatocellular carcinoma (HCC). We investigated the impact of HBeAg status at the onset of antiviral treatment on the risk of HCC. METHODS: The incidence of HCC was evaluated in Korean patients with chronic hepatitis B who started entecavir or tenofovir in either HBeAg-positive or HBeAg-negative phase. The results in the Korean cohort were validated in a Caucasian PAGE-B cohort. RESULTS: A total of 9143 Korean patients (mean age, 49.2 years) were included: 49.1% were HBeAg-positive and 49.2% had cirrhosis. During follow-up (median, 5.1 years), 916 patients (10.0%) developed HCC. Baseline HBeAg positivity was not associated with the risk of HCC in the entire cohort or cirrhotic subcohort. However, in the non-cirrhotic subcohort, HBeAg positivity was independently associated with a lower risk of HCC in multivariable (adjusted hazard ratio [aHR], 0.41; 95% confidence interval [CI], 0.26-0.66), propensity score-matching (aHR, 0.46; 95% CI, 0.28-0.76), and inverse probability weighting analyses (aHR, 0.44; 95% CI, 0.28-0.70). In the Caucasian cohort (n = 719; mean age, 51.8 years; HBeAg-positive, 20.3%; cirrhosis, 34.8%), HBeAg-positivity was not associated with the risk of HCC either in the entire cohort or cirrhotic subcohort. In the non-cirrhotic subcohort, none of the HBeAg-positive group developed HCC, although the difference failed to reach statistical significance (aHR, 0.21; 95% CI, 0.00-1.67). CONCLUSIONS: This multinational cohort study implies that HBeAg positivity at the onset of antiviral treatment seems to be an independent factor associated with a lower risk of HCC in patients with chronic hepatitis B without cirrhosis, but not in those with cirrhosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Jang H, Yoon JS, Park SY, et al. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2021. PMID: 34500103. doi:10.1016/j.cgh.2021.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。